Approaches to discovery and characterization of inhibitors of amyloid β-peptide polymerization

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1502, Issue 1, 2000, Pages 76-84

  Findeis, Mark A ^a  

^a Praecis Pharmaceuticals Inc   (United States)

Author keywords

Peptide; Aggregation; Alzheimer's disease; Amyloid; Inhibitor; Polymerization

Indexed keywords

AMYLOID; AMYLOID PRECURSOR PROTEIN; ANTHRACYCLINE; AZO DYE; BETA PEPTIDE; CONGO RED; RIFAMPICIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CELL STRAIN; DISSOCIATION CONSTANT; FIBER; HUMAN; HUMAN TISSUE; IC 50; LIGHT SCATTERING; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; REVIEW; TECHNIQUE;

ACRIDINES; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BENZOFURANS; CONGO RED; DOXORUBICIN; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; NEUROFIBRILLARY TANGLES; PEPTIDE FRAGMENTS; POLYMERS; PROTEIN BINDING; RIFAMPIN;

EID: 0034718206     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4439(00)00034-X     Document Type: Review

References (88)

1. Selkoe D.J. Alzheimer's disease: Genotypes, phenotype, and treatment. Science. 275:1997;630-631.
2. Diehl S.R. Sand in the sheets. Nat. Med. 1:1995;120-122.
3. Selkoe D.J. Missense on the membrane. Nature. 375:1995;734-735.
4. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 20:1997;154-159.
5. Haass C., Schlossmacher M.G., Hung A.Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B.L., Lieberburg I., Koo E.H., Schenk D., Teplow D.B., Selkoe D.J. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature. 359:1992;322-325.
6. Shoji M., Golde T.E., Ghiso J., Cheung T.T., Estus S., Shaffer L.M., Cai X.-D., McKay D.M., Tintner R., Frangione B., Younkin S.G. Production of the Alzheimer amyloid β protein by normal proteolytic processing. Science. 258:1992;126-129.
7. Sisodia S.S., Gallagher M. A role for the β-amyloid precursor protein in memory? Proc. Natl. Acad. Sci. USA. 95:1998;12074-12076.
8. Meziane H., Dodart J.-C., Mathis C., Little S., Clemens J., Paul S.M., Ungerer A. Memory-enhancing effects of secreted forms of the β-amyloid precursor protein in normal and amnestic mice. Proc. Natl. Acad. Sci. USA. 95:1998;12683-12688.
9. Pike C.J., Walencewicz A.J., Glabe C.G., Cotman C.W. In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 563:1991;311-314.
10. Shearman M.S., Ragan C.I., Iversen L.L. Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of β-amyloid-mediated cell death. Proc. Natl. Acad. Sci. USA. 91:1994;1470-1474.
11. Ueda K., Fukui Y., Kageyama H. Amyloid β protein-induced neuronal cell death: neurotoxic properties of aggregated amyloid β protein. Brain Res. 639:1994;240-244.
12. Mattson M.P., Rydel R.E. Amyloid ox-tox transducers. Nature. 382:1996;674-675.
13. Yan S.D., Chen X., Fu J., Chen M., Zhu H., Roher A., Slattery T., Zhao L., Nagashima M., Morser J., Migheli A., Nawroth P., Stern D., Schmidt A.M. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature. 382:1996;685-691.
14. El Khoury J., Hickman S.E., Thomas C.A., Cao L., Silverstein S.C., Loike J.D. Scavenger receptor-mediated adhesion of microglia to β-amyloid fibrils. Nature. 382:1996;716.
15. 1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA. 95:1998;6448-6453.
16. Calhoun M.E., Wiederhold K.-H., Abramowski D., Phinney A.L., Probst A., Sturchler-Pierrat C., Staufenbiel M., Sommer B., Jucker M. Neuron loss in APP transgenic mice. Nature. 395:1998;755-756.
17. Schenk D.B., Rydel R.E., May P., Little S., Panetta J., Lieberburg I., Sinha S. Therapeutic approaches related to amyloid-β peptide and Alzheimer's disease. J. Med. Chem. 38:1995;4141-4154.
18. Lansbury P.T. Jr. Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease. Curr. Opin. Chem. Biol. 1:1997;260-267.
19. Parnetti L. Cognitive enhancement therapy for Alzheimer's disease. Drugs. 53:1997;752-768.
20. Jarrett J.T., Berger E.P., Lansbury P.T. Jr. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation implications for the pathogenesis of Alzheimer's disease. Biochemistry. 32:1993;4693-4697.
21. Jarrett J.T., Lansbury P.T. Jr. Seeding 'one-dimensional crystallization' of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell. 73:1993;1055-1058.
22. M.A. Findeis and S.M. Molineaux, Design and testing of inhibitors of fibril formation, in: R. Wetzel (Ed.), The Process and Products of Protein Misassembly, Methods in Enzymology, Vol. 309, pp. 476-488.
23. Le Vine H. III. Thioflavine T interaction with synthetic Alzheimer's disease β-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 2:1993;404-410.
24. Le Vine H. III. Thioflavine T interaction with amyloid β-sheet structures. Amyloid. 2:1995;1-6.
25. Naiki H., Keiichi H., Masanori H., Takeda T. Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavine T. Anal. Biochem. 177:1989;244-249.
26. Wood S.J., Mackenzie L., Maleef B., Hurle M.R., Wetzel R. Selective inhibition of Aβ fibril formation. J. Biol. Chem. 271:1996;4086-4092.
27. Han H., Cho C.-G., Lansbury P.T. Jr. Technetium complexes for the quantitation of brain amyloid. J. Am. Chem. Soc. 118:1996;4506-4507.
28. Esler W.P., Stimson E.R., Ghilardi J.R., Vinters H.V., Lee J.P., Mantyh P.W., Maggio J.E. In vitro growth of Alzheimer's disease β-amyloid plaques displays first-order kinetics. Biochemistry. 35:1996;749-757.
29. Tjernberg L.O., Näslund J., Lindqvist F., Johansson J., Karlström A.R., Thyberg J., Terenius L., Nordstedt C. Arrest of β-amyloid fibril formation by a pentapeptide ligand. J. Biol. Chem. 271:1996;8545-8548.
30. Lomakin A., Chung D.S., Benedek G.B., Kirschner D.A., Teplow D.B. On the quantitation and growth of amyloid β-protein fibrils: detection of nuclei and quantitation of rate constants. Proc. Natl. Acad. Sci. USA. 93:1996;1125-1129.
31. Pallitto M.M., Ghanta J., Heinzelman P., Kiessling L.L., Murphy R.M. Recognition sequence design for peptidyl modulators of β-amyloid aggregation and toxicity. Biochemistry. 38:1999;3570-3578.
32. Inouye H., Fraser P.E., Kirschner D.A. Structure of β-crystallite assemblies formed by Alzheimer β-amyloid protein analogues: analysis by x-ray diffraction. Biophys. J. 64:1993;502-519.
33. Fraser P.E., McLachlan D.R., Surewicz W.K., Mizzen C.A., Snow A.D., Nguyen J.T., Kirschner D.A. Conformation and fibrillogenesis of Alzheimer Ab peptides with selected substutution of charged residues. J. Mol. Biol. 244:1994;64-73.
34. Harper J.D., Wong S.S., Lieber C.M., Lansbury P.T. Jr. Observation of metastable Aβ amyloid protofibrils by atomic force microscopy. Chem. Biol. 4:1997;119-125.
35. Harper J.D., Lieber C.M., Lansbury P.T. Jr. Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid β-protein. Chem. Biol. 4:1997;951-959.
36. Kowalewski T., Holtzman D.M. In situ atomic force microscopy study of Alzheimer's β-amyloid peptide on different substrates: New insights into mechanism of β-sheet formation. Proc. Natl. Acad. Sci. USA. 96:1999;3688-3693.
37. Goldsbury C., Kistler J., Aebli U., Arvinte T., Cooper G.J.S. Watching amyloid fibrils grow by time-lapse atomic force microscopy. J. Mol. Biol. 285:1999;33-39.
38. Lorenzo A., Yankner B.A. β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo Red. Proc. Natl. Acad. Sci. USA. 91:1994;12243-12247.
39. Podlisny M.B., Walsh D.M., Amarante P., Ostaszewski B.L., Stimson E.R., Maggio J.E., Teplow D.B., Selkoe D.J. Oligomerization of endogenous and synthetic amyloid β-protein at nanomolar levels in cell culture and stabilization of monomer by Congo Red. Biochemistry. 37:1998;3602-3611.
40. The United States of America as represented by the Department of Health and Human Services (B. Caughey and R. Race), Inhibition of diseases associated with amyloid formation, US-5,276,059, 1994.
41. Klunk W.E., Debnath M.L., Pettegrew J.W. Development of small molecule probes for the β-amyloid protein of Alzheimer's disease. Neurobiol. Aging. 15:1994;691-698.
42. Klunk W.E., Debnath M.L., Koros A.M., Pettegrew J.W. Chrysamine G, a lipophilic analogue of Congo Red, inhibits A β-induced toxicity in PC12 cells. Life Sci. 63:1998;1807-1814.
43. Namba Y., Kawatsu K., Izumi S., Ueki A., Ikeda K. Neurofibrillary tangles and senile plaques in brain of elderly leprosy patients. Lancet. 340:1992;978.
44. Kimura T., Goto M. Existence of senile plaques in the brains of elderly leprosy patients. Lancet. 342:1993;1364.
45. Tomiyama T., Asano S., Suwa Y., Morita T., Kataoka K., Mori H., Endo N. Rifampicin prevents the aggregation and neurotoxicity of amyloid β protein in vitro. Biochem. Biophys. Res. Commun. 204:1994;76-83.
46. Teijin Limited (T. Tomiyama, Y. Suwa, S. Asano, K. Kataoka, T. Morita and N. Endo), Amyloid β-protein agglutination and/or deposition inhibitor, EP-0675126-A1, 1995.
47. Tomiyama T., Shoji A., Kataoka K., Suwa Y., Asano S., Kaneko H., Endo N. Inhibition of amyloid β protein aggregation and neurotoxicity by rifampicin. J. Biol. Chem. 271:1996;6839-6844.
48. Merlini G., Ascari E., Amboldi N., Bellotti V., Arbustini E., Perfetti V., Ferrari M., Zorzoli I., Marinone M.G., Garini P., Diegoli M., Trizio D., Ballinari D. Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc. Natl. Acad. Sci. USA. 92:1995;2959-2963.
49. Tagliavini F., McArthur R.A., Canciani B., Giaccone G., Porro M., Bugiani M., Lievens P.M.-J., Bugiani O., Peri E., Dall'Ara P., Rocchi M., Poli G., Forloni G., Bandiera T., Varasi M., Suarato A., Cassutti P., Cervini M.A., Lansen J., Salmona M., Post C. Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. Science. 276:1997;1119-1122.
50. S.J. Hays, H. LeVine, III and J.D. Scholten, Inhibition of Amyloidosis by 9-Acridinones, US-5,972,956, 1999.
51. Howlett D.R., Perry A.E., Godfrey F., Swatton J.E., Jennings K.H., Spitzfaden C., Wadsworth H., Wood S.J., Markwell R.E. Inhibition of fibril formation in β-amyloid peptide by a novel series of benzofurans. Biochem. J. 340:1999;283-289.
52. Hilbich C., Kisters-Woike B., Reed J., Masters C.L., Beyreuther K. Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease βA4 peptides. J. Mol. Biol. 228:1992;460-473.
53. Praecis Pharmaceuticals Incorporated (M.A. Findeis, H. Benjamin, M.B. Garnick, M.L. Gefter, A. Hundal, L. Kasman, G. Musso, E.R. Signer, J. Wakefield and M. Reed), Modulators of β-Amyloid Peptide Aggregation, US-5,817,626, 1998.
54. Praecis Pharmaceuticals Incorporated (M.A. Findeis, H. Benjamin, M.B. Garnick, M.L. Gefter, A. Hundal, L. Kasman, G. Musso, E.R. Signer, J. Wakefield and M. Reed), Modulators of βa-Amyloid Peptide Aggregation, US-5,854,215, 1998.
55. Findeis M.A., Musso G.M., Arico-Muendel C.C., Benjamin H., Hundal A.M., Lee J.-J., Chin J., Kelley M., Wakefield J., Hayward N.J., Molineaux S.M. Modified-peptide inhibitors of amyloid β-peptide polymerization. Biochemistry. 38:1999;6791-6800.
56. M.A. Findeis and S.M. Molineaux, Discovery and characterization of peptidoorganic inhibitors of amyloid β-peptide polymerization, in: A. Fisher, I. Hanin and M. Yoshida (Eds.), Progress in Alzheimer's and Parkinson's Diseases, Plenum, New York, 1998, 191-195.
57. Findeis M.A., Musso G.M., Benjamin H., Chin J., Hayward N., Hundal A.M., Kasman L., Kelley M., Lee J.J., Reed M., Wakefield J., Molineaux S.M. Discovery of PPI-368, a potent inhibitor of amyloid β-peptide polymerization. Soc. Neurosci. Abstr. 22:1996;1945.
58. Molineaux S.M., Chin J., Lee J.J., Kelley M., Kubasek W., Wakefield J., Zhang M.H., Zhang X., Molineaux C.J., Musso G.M., Findeis M.A. Biochemical and biological characterization of PPI-368, a potent inhibitor of amyloid β-peptide polymerization. Soc. Neurosci. Abstr. 22:1996;1659.
59. Praecis Pharmaceuticals Incorporated (M.A. Findeis, H. Benjamin, M.B. Garnick, M.L. Gefter, A. Hundal, L. Kasman, G. Musso, E.R. Signer, J. Wakefield, M. Reed, S. Molineaux, W. Kubasek, J. Chin, J.-J. Lee and M. Kelley), A-β Peptides that Modulate β-Amyloid Aggregation, US-5,854,204, 1998.
60. Pharmaceutical Peptides Incorporated (M.A. Findeis, H. Benjamin, M.B. Garnick, M.L. Gefter, A. Hundal, L. Kasman, G. Musso, E.R. Signer, J. Wakefield, et al.), Modulators of Amyloid Aggregation, WO-9628471-A1, 1996.
61. Praecis Pharmaceuticals Incorporated (M.A. Findeis, M.L. Gefter, G. Musso, E.R. Signer, J. Wakefield, S. Molineaux, J. Chin, J.-J. Lee, M. Kelley, S. Komar-Panicucci, C.C. Arico-Muendel, K. Phillips and N.J. Hayward), Modulators of β-amyloid peptide aggregation comprising D-amino acids, WO-9808868-A1, 1998.
62. Pachter J.S., Antic A.M., Weltzein R., Andjelkovic A.V., Dzenko K.A., Kelley M., Phillips K., Wakefield J., Findeis M., Molineaux S. Aβ1-40 induced neurocytopathic activation of human monocytes is blocked by Aβ peptide aggregation inhibitors. Neurobiol. Aging. 19:1998;S128.
63. Weltzein R., Andjelkovic A., Kelley M., Phillips K., Wakefield J., Findeis M., Molineaux S. Phagocytosis of β-amyloid: A possible requisite for neurotoxicity. J. Neuroimmunol. 90:1998;32.
64. Soto C., Kindy M.S., Baumann M., Frangione B. Inhibition of Alzheimer's amyloidosis by peptides that prevent β-sheet conformation. Biochem. Biophys. Res. Commun. 226:1996;672-680.
65. Soto C., Sigurdsson E.M., Morelli L., Kumar R.A., Castaño E.M., Frangione B. β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis Implications for Alzheimer's therapy. Nat. Med. 4:1998;822-826.
66. S. Soto-Jara, M.H. Baumann and B. Frangione, Peptides and Pharmaceutical Compositions thereof for Treatment of Disorders or Diseases Associated with Abnormal Protein Folding into Amyloid or Amyloid-Like Deposits, US-5,948,763, 1999.
67. Ghanta J., Shen C.-L., Kiessling L.L., Murphy R.M. A strategy for designing inhibitors of β-amyloid toxicity. J. Biol. Chem. 271:1996;29525-29528.
68. Kisilevsky R., Lemieux L.J., Fraser P.E., Kong X., Hultin P.G., Szarek W.A. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat. Med. 1:1995;143-148.
69. Queen's University at Kingston (W.A. Szarek and X. Kong) Phosphonocarboxylate Compounds for Treating Amyloidosis, US-5,869,469, 1999.
70. R. Kisilevsky, W. Szarek and D. Weaver, Method for Treating Amyloidosis, US-5,972,328, 1999.
71. Small G.W., Mazziotta J.C., Collins M.T., Baxter L.R., Phelps M.E., Mandlekern M.A., Kaplan A., LaRue A., Adamson C.F., Chang L., Guze B.H., Corder E.H., Saunders A.M., Haines J.L., Pericak-Vance M.A., Roses A.D. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA. 273:1995;942-947.
72. Reiman E.M., Caselli R.J., Yun L.S., Chen K., Bandy D., Minoshima S., Thibodeau S.N., Osborne D. Preclinical evidence of Alzheimer disease in persons homozygous for the ε4 allele for apolipoprotein E. N. Engl. J. Med. 334:1996;752-758.
73. Evans K.C., Berger E.P., Cho C.-G., Weisgraber K.H., Lansbury P.T. Jr. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc. Natl. Acad. Sci. USA. 92:1995;763-767.
74. Wood S.J., Chan W., Wetzel R. Seeding of Aβ fibril formation is inhibited by all three isotypes of apolipoprotein E. Biochemistry. 35:1996;12623-12628.
75. Wood S.J., Chan W., Wetzel R. An ApoE-Aβ inhibition complex in Aβ fibril extension. Chem. Biol. 3:1996;949-956.
76. Solomon B., Koppel R., Frankel D., Hanan-Aharon E. Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. USA. 94:1997;4109-4112.
77. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:1999;173-177.
78. Camilleri P., Haskins N.J., Howlett D.R. β-Cyclodextrin interacts with the Alzheimer amyloid β-A4 peptide. FEBS Lett. 341:1994;256-258.
79. Salomon A.R., Marcinowski K.J., Friedland R.P., Zagorski M.G. Nicotine inhibits amyloid formation by the β-peptide. Biochemistry. 35:1996;13568-13578.
80. Pappolla M., Bozner P., Soto C., Shao H., Robakis N.K., Zagorski M., Frangione B., Ghiso J. Inhibition of Alzheimer β-fibrillogenesis by melatonin. J. Biol. Chem. 273:1998;7185-7188.
81. Peterson S.A., Klabunde T., Lahuel H.A., Purkey H., Sacchetini J.C., Kelly J.W. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc. Natl. Acad. Sci. USA. 95:1998;12956-12960.
82. R. Wetzel, Amyloid, prions, and other protein aggregates, Methods Enzymol. 309 (1999).
83. Sinha S., Lieberburg I. Cellular mechanisms of β-amyloid production and secretion. Proc. Natl. Acad. Sci. USA. 96:1999;11049-11053.
84. Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., Teplow D.B., Ross S., Amarante P., Loeloff R., Luo Y., Fisher S., Fuller J., Edenson S., Lile J., Jarosinski M.A., Biere A.L., Curran E., Burgess T., Louis J.-C., Collins F., Treanor J., Rogers G., Citron M. β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 286:1999;735-741.
85. Bohrmann B., Tjernberg L., Kuner P., Poli S., Levet-Trafit B., Näslund J., Richards G., Huber W., Döbeli H., Nordstedt C. Endogenous proteins controlling amyloid β-peptide polymerization. J. Biol. Chem. 274:1999;15990-15995.
86. Cruz L., Urbanc B., Buldyrev S.V., Christie R., Gómez-Isla T., Havlin S., McNamara M., Stanley H.E., Hyman B.T. Aggregation and disaggregation of senile plaques in Alzheimer disease. Proc. Natl. Acad. Sci. USA. 94:1997;7612-7616.
87. Coelho T. Familial amyloid polyneuropathy: new developments in genetics and treatment. Curr. Opin. Neurol. 9:1996;355-359.
88. Dubrey S., Mendes L., Skinner M., Falk R.H. Resolution of heart failure in patients with AL amyloidosis. Ann. Intern. Med. 125:1996;481-484.